Acumen Pharmaceuticals, Inc. (ABOS) Form 8-K — Oct 26, 2026
$ABOSForm 8-KItems 2.02, 7.01, 9.01Filed Oct 26, 2026, 7:09 AM ET0001628280-26-067129Original filing
Acumen Pharmaceuticals reported Q3 2026 results with a net loss of $25.4 million and cash of $78.6 million, down from $110.2 million at the end of June. The company confirmed it expects topline results from the 542-patient ALTITUDE-AD Phase 2 study of sabirnetug in early Alzheimer's disease in November 2026. Cash is expected to fund operations only into early 2027, so Acumen will likely need additional financing regardless of the Phase 2 outcome. R&D expenses fell slightly year-over-year to $21.1 million as ALTITUDE-AD trial costs wound down.
Key figures
- Revenue
- 0
- Total Assets
- 85565000
- Cash Position
- 78600000
- Net loss q3 2025
- 26500000
- Phase2 enrollment
- 542
- Cash prior quarter
- 110200000
- Ga expense q3 2026
- 4700000
- Rd expense q3 2025
- 22000000
- Rd expense q3 2026
- 21100000
- Shares outstanding
- 72327320
- Nine month net loss
- 78824000
- Stockholders equity
- 34610000
- Loss from operations q3 2026
- 25800000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.